HOME >> MEDICINE >> NEWS
Many heart attack patients still not getting emergency clot-busting treatment

ANN ARBOR, Mich. Far more of todays heart attack patients receive emergency angioplasty treatment or clot-busting drugs to re-open their clogged heart arteries than even a decade ago, a new study finds.

But 10 percent of patients who could benefit from this urgent treatment which is known to save lives and prevent lasting damage to the heart muscle dont get it at all, the study shows.

And the chance of missing out on lifesaving emergency treatment was highest among those patients whose heart attack symptoms dont include typical symptoms like chest pain, those who didnt reach the hospital until six or more hours after the start of their attack, women, people over age 75, and non-white people.

The study, published in the American Journal of Medicine by a team led by cardiologists from the University of Michigan Cardiovascular Center and the Yale University School of Medicine, is based on data from 238,291 patients who had had a type of heart attack for which this therapy is appropriate between 1994 and 2003.

Its the most current and comprehensive look at the use of emergency reperfusion a term that describes treatments that can break up blood clots and other blockages in the tiny blood vessels of the heart and restore blood flow to the heart muscle.

In the ten-year study period, the percentage of patients who could have received emergency reperfusion but didnt declined from more than 20 percent to 10 percent a notable achievement that the authors attribute to the increasing evidence of the benefit of emergency angioplasty, and the rise in the availability of the treatment at American hospitals and concerted national efforts to improve care.

The database used for the study, called the National Registry of Myocardial Infarction, includes detailed information about each patients condition that can be used to determine if they would meet the criteria to receive emergency angioplasty or treatment wi
'"/>

Contact: Kara Gavin
kegavin@umich.edu
734-764-2220
University of Michigan Health System
3-Aug-2007


Page: 1 2 3 4

Related medicine news :

1. A broader look at cardiac CTA images often finds diseases/disorders beyond the heart
2. Drug for cluster headaches may cause heart problems
3. Reductive stress linked to heart disease
4. Novel candidate biomarker for heart failure also strongly predicts risk of death
5. New heart disease risk score will help minimize health inequalities
6. Metabolic syndrome points to heart health
7. Herceptin does not increase heart failure in patients long term
8. Fat protein cuts blood vessel inflammation, may help heart, Jefferson scientists find
9. Mayo researchers discover overdiagnosis of long QT heart syndrome
10. Exercise test may help predict mortality risk in heart failure patients
11. Mercurys link to heart disease begins in blood vessel walls

Post Your Comments:
(Date:5/20/2013)... (PRWEB) May 20, 2013 This summer, ... the world will make the pilgrimage to San Diego, ... annual Digital Health Summer Summit produced by ... a unique forum to showcase the latest digital health ... practices, and network with some of industry’s most brilliant ...
(Date:5/20/2013)... May 20, 2013 For more than ... waged a battle against drug and alcohol abuse around ... released its first guide to help Italian speakers reverse ... by the European Monitoring Centre for Drugs and Drug ... have used cannabis in the last year. As a ...
(Date:5/20/2013)... HealthDay Reporter , , MONDAY, May 20 (HealthDay News) -- ... out in the late 1990s is more effective than ... contends. Teenagers who received four shots with the ... were 2 years old were significantly less likely to ... in California, compared to children who received all of ...
(Date:5/20/2013)... What is it about toothpaste that transforms the sweet ... the solution to that mysterious sensory phenomenon in ... the American Chemical Society,s award-winning Bytesize Science ... from the world,s largest scientific society, explains that the ... lauryl sulfate, or SLS for short. When you brush ...
(Date:5/20/2013)... MAYWOOD, Il. - Nearly three out of ... disorders during their pregnancies, a Loyola University Medical Center ... only minimal impacts on pregnant women,s quality of life, ... Scott Graziano, MD and Payton Johnson was presented during ... Clinical Meeting in New Orleans. , One hundred and ...
Breaking Medicine News(10 mins):Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 2Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 3Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 4Health News:First Narconon Cannabis Abuse Prevention Guide Takes Aim at Drug Abuse Statistics for Italian Youth 2Health News:Study: Older Whooping Cough Vaccine More Effective 2Health News:Study: Older Whooping Cough Vaccine More Effective 3Health News:72 percent of pregnant women experience constipation and other bowel problems 2
(Date:5/20/2013)... 2013  AbbVie (NYSE: ABBV ) ... clinical study called SONAR (Study Of Diabetic Nephropathy ... investigational compound atrasentan - when added to standard of ... with stage 2 to 4 chronic kidney disease ... large, multinational, double-blind, placebo-controlled clinical study that is ...
(Date:5/19/2013)... ORLANDO, Fla. , May 19, 2013 /PRNewswire/ ... power and low temperature radiofrequency (RF) energy is ... and eliminates or reduces the need for medication ... long-term assessment presented today at the Digestive Disease ... Orlando, Florida . ...
(Date:5/17/2013)... SHANGHAI , May 17, 2013 Medical ... drug nor a biological product. In light of their ... trail evaluations are much more complicated than drug trails ... only evaluates MD safety instead of evaluating both safety ... the US FDA (which is the same as the ...
Breaking Medicine Technology:AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 2Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 3Statistical Challenges in Medical Device Trail Evaluation 2
Cached News: